Abstract
Background
Cardiotoxicity, produced as an adverse effect of anticancer therapy, is a common issue during cancer treatment. Acute coronary syndrome, myocarditis, arrhythmias, or heart failure can all be symptoms of this issue. Little is known about its occurrence among Saudi Arabian cancer patients. This study aims to investigate factors linked to anticancer therapy-related cardiotoxicity.
Methods
A retrospective study was conducted from April 2020 to May 2022 at the King Khalid Hospital, Najran, Saudi Arabia. The study included adult cancer patients receiving anticancer therapy, regardless of their cardiovascular disease history. Univariate analysis was used to investigate factors associated with the occurrence of cardiotoxicity related to anticancer therapy.
Results
Of 78 patients receiving anticancer therapy, cardiotoxicity occurred in 12 (15.4%) patients. The mean age was 56.5 ± 13.4 years, with 33.3% aged over 65 years. Comorbidities included hypertension (44; 56.4%), diabetes (41; 52.6%), dyslipidemia (13; 16.7%), smoking (16; 20.5%), heart disease (6; 7.7%), trastuzumab use (9; 11.5%), and chronic kidney disease (2; 2.6%). The most common cancers were breast cancer and gastrointestinal cancer (27.6% each). Monoclonal anticancer agents 35 (46.1%) and alkylating agents 29 (38.2%) were commonly used chemotherapies. Cardiac protective agents were used in 16 (21.1%) of patients, with angiotensin-converting enzyme (ACE) inhibitors 15 (19.7%) and statins (13; 17.1%) being the most prescribed. Baseline ejection fraction (EF) was normal in 69 (90.8%) of cases. The follow-up duration was 1.93 ± 1.90 years. A drop in EF occurred in five (6.6%) of cases. Dyslipidemia (OR: 0.12; 95% CI: 0.03-0.47, p=0.002), previous heart disease (OR: 0.14; 95% CI: 0.02-0.81, p=0.029), and impaired baseline EF (p=0.029) were associated with increased risk of cardiotoxicity. Statin (OR: 0.22; 95% CI: 0.05 to 0.84, p=0.028) and antiplatelet agents (OR: 0.19; 95% CI: 0.03 to 1.01, p=0.051) were protective agents against cardiac toxicity.
Conclusion
Effective anti-cancer therapy may be accompanied by an increased risk of cardiotoxicity. In this study, a history of prior heart disease, dyslipidemia, low baseline ejection fraction, and the administration of multiple anticancer therapy agents was associated with cardiotoxicity. Proactive management strategies aimed at mitigating the potential cardiotoxic effects of anti-cancer therapies are crucial.
Keywords: saudi arabia, najran, cardiac toxicity, chemotherapy, cancer
Introduction
The cardiotoxic effects of anticancer therapy were initially evaluated in late 1970, as an increased incidence of heart failure was observed among cancer patients following the initiation of anthracycline-based chemotherapy [1]. Such an issue became even more apparent with the advancement of cancer screening and detection, and the earlier, and sometimes longer, use of chemotherapeutics among cancer patients, which led inevitably to increased anticancer therapy-related adverse events [2].
Cancer therapies include various drug agents such as molecular target therapies, cytotoxic chemotherapy, and mediastinal irradiation [3]. There are various pathophysiological mechanisms, depending on the drug group, by which anticancer may affect the normal structure or function of the heart such as myocyte damage, ischemia, conduction, rhythm disturbances, left ventricular dysfunction, cardiac failure, and several other cardiovascular complications [4-6]. The most prevalent chemotherapeutic treatments connected to significant cardiac events include anthracyclines, alkylating agents (cyclophosphamide, cisplatin), and taxanes (paclitaxel, docetaxel) [3].
The risk factors of cardiovascular disease (CVD) and cancer suggest a possible overlapped pathogenesis [7]. Aging, physical inactivity, smoking, hypertension, diabetes mellitus, and inflammation appear to contribute to the progression and advancement of both entities [8].
The European Society of Cardiology provided a set of thorough recommendations regarding the pre-treatment assessment, comorbidities management, and long-term surveillance of cancer patients receiving cardiotoxic drugs [9]. Nevertheless, the complexity of patients necessities interdisciplinary cardio-oncology cooperation to provide the possible outcomes [10].
The precise incidence of cardiac toxicity and the extent of adherence to cardiac monitoring recommendations among cancer patients in Saudi Arabia are areas of limited knowledge [8]. Consequently, this study aims to investigate the factors associated with the occurrence of cardiotoxicity among adult cancer patients who receive anticancer therapy at the oncology center of King Khalid Hospital in Najran, Saudi Arabia. By elucidating these factors, we aim to contribute to the existing academic understanding of cardiotoxicity in the context of anticancer treatments and provide valuable insights for clinical practice and patient care.
Materials and methods
Study design
A retrospective study was conducted at the oncology center of King Khalid Hospital in Najran, Saudi Arabia, focused on anticancer-induced cardiotoxicity in adult cancer patients who underwent anticancer therapy spanning from April 2020 to May 2022. Patients who developed cardiotoxicity continued their remaining therapy, either with the medication removed from the regimen or with a full change of regimen. Ethical approval for the study was obtained from the Ethics Research Committees of King Khalid Hospital, ensuring compliance with the ethical principles stipulated in the Declaration of Helsinki.
Inclusion criteria: This study included adult patients (≥ 18 years) who received anticancer therapy at our center and had undergone left ventricular ejection fraction (LVEF) testing before and after anticancer therapy.
Exclusion criteria: Patients without LVEF test results before or after chemotherapy administration and elderly patients with advanced or terminal diseases were excluded.
The study protocol and main outcome
LVEF assessments were routinely conducted at baseline and three and six months after initiating chemotherapy. Cardiotoxicity was defined based on the criteria established by Guglin et al., which encompassed an LVEF value below 50% or a reduction of LVEF by 10% or more from baseline, along with symptomatic heart failure, even in the absence of a decline in LVEF [9,10]. The primary outcome was the occurrence of cardiac toxicity during the course of chemotherapy. The secondary outcome was to identify the factors associated with cardiotoxicity.
Data collection
Relevant data from electronic records and/or medical charts of eligible cancer patients were collected using a structured data collection format. The collected information included demographic details at the start of anticancer therapy, underlying cardiac conditions, comorbidities, histological cancer type, stage, tumor site, drug regimen, the total number of cycles, administration of cardiac protective agents, concurrent use of cancer chemotherapy, radiotherapy, or endocrine therapy, as well as pre-and post-treatment LVEF values.
Statistical analysis
Descriptive statistics were utilized to present quantitative variables in terms of means and standard deviations while qualitative variables were expressed as frequencies and percentages. The normality of the data was assessed using the Kolmogorov-Smirnov test. To compare patients in the cardiac toxicity and non-cardiac toxicity groups, univariate analysis was performed employing independent samples T-test or Mann-Whitney test for quantitative variables and chi-square or Fisher's exact test for qualitative variables. A significance level of p < 0.05 was considered statistically significant. The statistical analysis was carried out using IBM SPSS version 18 software (IBM Corp., Armonk, New York).
Results
Among the 78 cancer patients who underwent anticancer therapy, cardiotoxicity was observed in 12 individuals (15.4%). The mean age of the patients was 56.5 ± 13.4 years (ranging from 32 to 81 years), with 26 patients (33.3%) being older than 65 years. A majority of the patients (51; 65.4%) were female. Prevalence rates of hypertension, smoking, dyslipidemia, heart disease, diabetes, trastuzumab use, chronic kidney disease, and previous percutaneous coronary intervention were reported in 44 (56.4%), 16 (20.5%), 13 (16.7%), 6 (7.7%), 41 (52.6%), 9 (11.5%), 2 (2.6%), and 1 (1.3%) patient(s), respectively. The most common types of cancer observed were breast cancer (27.6%) and gastrointestinal cancer (27.6%). A majority of the patients (55.3%) were in the metastatic stage. Monoclonal anticancer agents and alkylating agents were the most frequently used anticancer therapy subgroups, accounting for 35 (46.1%) and 29 (38.2%) cases, respectively. Cardiac protective agents were administered to 16 (21.1%) patients, with ACE inhibitors and statins being the most commonly prescribed for 15 (19.7%) and 13 (17.1%) patients, respectively. The baseline ejection fraction was found to be normal in the majority of cases, with 69 (90.8%) patients exhibiting normal values (Table 1).
Table 1. The patient's characteristics.
Abbreviations: RCVP: rituximab with cyclophosphamide, vincristine, and prednisone; RCHOP: rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone, AC: doxorubicin and cyclophosphamide; ACE: angiotensin-converting enzyme
| Variables | N (%) |
| Age (year) Mean (SD) | 56.5 (13.3) (range 32 - 81) |
| Age group | |
| ≥65 years | 51 (67.1%) |
| <65 years | 25 (32.9%) |
| Gender | |
| Male | 26 (34.2%) |
| Female | 50 (65.8%) |
| Smoking | 16 (21.1%) |
| Cardiotoxicity | 12 (15.4) |
| Percutaneous coronary intervention | 1 (1.3%) |
| Hypertension | 43 (56.6%) |
| Diabetes | 40 (52.6%) |
| Heart disease | 6 (7.9%) |
| Chronic kidney disease | 2 (2.6%) |
| Trastuzumab using | 9 (11.8%) |
| Dyslipidemia | 13 (17.1%) |
| Site of cancer | |
| Lymphoma | 8 (10.5%) |
| Breast | 21 (27.6%) |
| Urologic cancer | 8 (10.5%) |
| Gastrointestinal cancer | 21 (27.6%) |
| Gynecological cancer | 7 (9.2%) |
| Lung | 3 (3.9%) |
| Malignant melanoma | 4 (5.3%) |
| Head and neck cancer | 3 (3.9%) |
| Other cancer | 1 (1.3%) |
| Cancer stage | |
| Metastatic | 42 (55.3%) |
| Non-metastatic | 34 (44.7%) |
| Use of cardiac protective agents | 16 (21.1%) |
| Cardiac protective agents | |
| Betablocker | 10 (13.2%) |
| ACE inhibitors | 15 (19.7%) |
| Statins | 13 (17.1%) |
| Antiplatelets | 7 (9.2%) |
| Number of chemotherapy cycles used | |
| < 5 cycles | 33 (43.4%) |
| Between 6-10 cycles | 30 (39.5%) |
| ≥10 cycles | 13 (17.1%) |
| Bassline ejection fraction | |
| Normal (55 or more) | 69 (90.8%) |
| Between 50 -54% (Borderline low) | 1 (1.3%) |
| Between 36-49% (impaired) | 6 (7.9%) |
| A drop in ejection fraction during treatment | 5 (6.6%) |
| Anticancer therapy protocol | |
| RCVP | 3 (3.9%) |
| Docetaxel | 5 (6.6%) |
| Folfox | 11 (14.5%) |
| RCHOP | 2 (2.6%) |
| AC | 8 (10.5%) |
| Carbo Taxol | 3 (3.9%) |
| Xelox | 5 (6.6%) |
| Paclitaxel | 4 (5.3%) |
| Other | 35 (46.1%) |
| Anticancer therapy subgroups | |
| Monoclonal anticancer use | 35 (46.1%) |
| Alkylating agent users | 29 (38.2%) |
| Anthracyclines | 16 (21.1%) |
| Other agents use | 2 (2.6%) |
| Taxane users | 11 (14.5%) |
Follow-up duration and changes in EF during treatments
The average follow-up duration in this study was 1.93 ± 1.90 years. Out of the patients, five (6.6%) experienced a decrease in ejection fraction (EF) during their treatment period. Interestingly, the decrease in EF was less pronounced among those without cardiac toxicity (Table 2).
Table 2. The association between the drop of EF during treatment and factors such as cardiac toxicity occurrence.
| Variables | Sub variable | Total (n=78) N (%) | A drop of EF during treatment | Univariate analysis | P-value | |
| No n (%) 73(93.6) | Yes n (%) 5(6.4) | OR (95 % CI) | ||||
| Cardiac toxicity | No | 66(84.6) | 65(98.5) | 1(1.5) | 0.03 (0.003 to 0.31) | 0.003 |
| Yes | 12(15.4) | 8(66.7) | 4(33.3) | Reference group | ||
Risk factors for cardiac toxicity
The univariate analysis revealed that individuals with dyslipidemia had a higher chance of experiencing cardiac toxicity (odds ratio (OR) 0.12; 95% confidence interval (CI) 0.03 to 0.47, p=0.002), as did those with a previous history of heart disease (OR: 0.14; 95% CI: 0.02 to 0.81, p=0.029), and those with impaired baseline EF (p=0.029). Table 3 provides an overview of patient factors and their association with cardiac toxicity (Table 3).
Table 3. Patients' factors and their association with cardiac toxicity.
| Variables | Sub variable | Total (n=78) N (%) | Outcome cardiac toxicity | Univariate analysis | P-value | |
| No n (%) 66(84.6) | Yes n (%) 12(15.4) | OR (95 % CI) | ||||
| Age | <65 years | 52(66.7) | 46(88.5) | 6(11.5) | 0.43 (0.12 to 1.51) | 0.191 |
| ≥65 years | 26(33.3) | 20(76.9) | 6(23.1) | Reference group | ||
| Gender | Male | 27(34.6) | 25(92.6) | 2(7.4) | 0.32 (0.06 to 1.62) | 0.171 |
| Female | 51(65.4) | 41(80.4) | 10(19.6) | Reference group | ||
| Smoking | No | 62(79.5) | 53(85.5) | 9(14.5) | 0.73 (0.17 to 3.10) | 0.676 |
| Yes | 16(20.5) | 13(81.3) | 3(18.8) | Reference group | ||
| Hypertension | No | 34(43.6) | 27(79.4) | 7(20.6) | 2.02 (0.58 to 7.04) | 0.269 |
| Yes | 44(56.4) | 39(88.6) | 5(11.4) | Reference group | ||
| Diabetes | No | 37(47.4) | 30(81.1) | 7(18.9) | 1.68 (0.48 to 5.83) | 0.414 |
| Yes | 41(52.6) | 36(87.8) | 5(12.2) | Reference group | ||
| Trastuzumab use | No | 69(88.5) | 57(82.6) | 12(17.4) | - | 0.340 |
| Yes | 9(11.5) | 9(100.0) | 0(0.0) | Reference group | ||
| Heart disease | No | 72(92.3) | 63(87.5) | 9(12.5) | 0.14 (0.02 to 0.81) | 0.029 |
| Yes | 6(7.7) | 3(50.0) | 3(50.0) | Reference group | ||
| History of percutaneous intervention | No | 77(98.7) | 66(85.7) | 11(14.3) | - | 0.154 |
| Yes | 1(1.3) | 0(0.0) | 1(100.0) | Reference group | ||
| Chronic renal failure | No | 76(97.4) | 64(84.2) | 12(15.8) | - | 1.000 |
| Yes | 2(2.6) | 2(100.0) | 0(0.0) | Reference group | ||
| Dyslipidemia | No | 65(83.3) | 59(90.8) | 6(9.2) | 0.12 (0.03 to 0.47) | 0.002 |
| Yes | 13(16.7) | 7(53.8) | 6(46.2) | Reference group | ||
| Cycles number | <5 | 35(44.9) | 30(85.7) | 5(14.3) | 0.91 (0.15 to 5.43) | 0.924 |
| 6=10 | 30(38.5) | 25(83.3) | 5(16.7) | 1.10 (0.18 to 6.56) | 0.917 | |
| >10 | 13(16.7) | 11(84.6) | 2 (15.4) | Reference group | ||
| Bassline ejection fraction | Normal | 69 (90.8) | 8 (72.7) | 61 (93.8) | Reference group | 0.029 |
| Borderline | 1 (1.3) | 1 (9.1) | 0 (0.0) | |||
| Impaired | 6 (7.9) | 2 (18.2) | 4 (6.2) | |||
Association between cardiac toxicity and anticancer therapy subtype
There was a higher chance of cardiac toxicity among individuals who received specific anticancer therapy subtypes, including monoclonal anticancer, alkylating agents, anthracyclines, hormonal agents, or Taxan users, as well as those who received multiple anticancer therapy subtypes (OR: 2; 95% CI: 0.57 to 6.92 and OR: 1.17; 95% CI: 0.58 to 2.35, respectively). However, these associations were not found to be statistically significant, as indicated by the p-values of 0.274 and 0.653 (Table 4).
Table 4. The association between cardiac toxicity and anticancer therapy subtype.
| Variable | Subvariable | Total (n=78) N (%) | Outcome cardiac toxicity | Univariate analysis | P-value | |
| No n (%) 66(84.6) | Yes n (%) 12(15.4) | OR (95 % CI) | ||||
| Monoclonal anticancer users | No | 66(84.6) | 57(86.4) | 9(13.6) | 0.47 (0.10 to 2.08) | 0.324 |
| Yes | 12(15.4) | 9(75.0) | 3(25.0) | Reference group | ||
| Alkylating agent users | No | 48(61.5) | 41(85.4) | 7(14.6) | 0.85 (0.24 to 2.98) | 0.804 |
| Yes | 30(38.5) | 25(83.3) | 5(16.7) | Reference group | ||
| Anthracyclines users | No | 62(79.5) | 53(85.5) | 9(14.5) | 0.73 (0.17 to 3.10) | 0.676 |
| Yes | 16(20.5) | 13(81.3) | 3(18.8) | Reference group | ||
| Other agents' users | No | 76(97.4) | 64(84.2) | 12(15.8) | - | 1.000 |
| Yes | 2(2.6) | 2(100.0) | 0(0.0) | - | ||
| Taxane users | No | 67(85.5) | 56(83.6) | 11(16.4) | 0.50 (0.06 to 4.39) | 0.539 |
| Yes | 11(14.1) | 10(90.9) | 1(9.1) | Reference group | ||
| Anticancer therapy subtype | No | 28(35.9) | 22(78.6) | 6(21.4) | 2.00 (0.57 to 6.92) | 0.274 |
| Yes | 50(64.1) | 44(88.0) | 6(12.0) | Reference group | ||
| Number of anticancer therapies received | 0 | 28(35.9) | - | - | 1.17 (0.58 to 2.35) | 0.653 |
| 1 | 35(44.9) | |||||
| 2 | 10(12.8) | |||||
| 3 | 5(6.4) | |||||
Administration of cardiac protection during treatments
Cardiac protective agents were used in 16 (20.5%) of patients and ACE inhibitors and statins were the most commonly used. In univariate analysis, statin (OR: 0.22; 95% CI: 0.05 to 0.84, P=0.028) and antiplatelet (OR: 0.19; 95% CI: 0.03 to 1.01, P=0.051) were protective agents against cardiac toxicity and were statistically significant (Table 5).
Table 5. The effect of cardiac protective agents on cardiac toxicity.
| Variable | Subvariable | Total (n=78) N (%) | Outcome cardiac toxicity | Univariate analysis | P-value | |
| No n (%) 66(84.6) | Yes n (%) 12(15.4) | OR (95 % CI) | ||||
| Use of cardio-protective drugs | No | 62(79.5) | 54(87.1) | 8(12.9) | 0.44 (0.11 to 1.72) | 0.240 |
| Yes | 16(20.5) | 12(75.0) | 4(25.0) | Reference group | ||
| Beta-blocker | No | 68(87.2) | 59(86.8) | 9(13.2) | 0.35 (0.07 to 1.63) | 0.184 |
| Yes | 10(12.8) | 7(70.0) | 3(30.0) | Reference group | ||
| ACE inhibitors | No | 63(80.8) | 55(87.3) | 8(12.7) | 0.40 (0.10 to 1.56) | 0.188 |
| Yes | 15(19.2) | 11(73.3) | 4(26.7) | Reference group | ||
| Statins | No | 64(82.1) | 57(89.1) | 7(10.9) | 0.22 (0.05 to 0.84) | 0.028 |
| Yes | 14(17.9) | 9(64.3) | 5(35.7) | Reference group | ||
| Antiplatelets | No | 71(91.0) | 62(87.3) | 9(12.7) | 0.19 (0.03 to 1.01) | 0.051 |
| Yes | 7(9.0) | 4(57.1) | 3(42.9) | Reference group | ||
Discussion
Our analysis revealed that a previous history of heart disease, dyslipidemia, low baseline EF, and receiving multiple anticancer therapies were associated with cardiotoxicity occurrence. Additionally, there was an acceptable incidence rate of anti-cancer-related cardiotoxicity with precise adherence to the monitoring guidelines for cardiotoxicity. Additionally, statin and antiplatelet were protective agents against cardiac toxicity and were statistically significant. Overall, based on the utilized criteria, chemotherapy-induced cardiotoxicity was observed in 15.4% of the patients included in our study.
It is noteworthy that there is considerable variability in the incidence of cardiotoxicity among cancer patients, ranging from as low as 3.8% to as high as 37.5% in previous studies [11,12]. This variability suggests the presence of potential confounding factors or effect modifiers that contribute to the risk of cardiotoxicity. For instance, certain chemotherapeutic agents, such as doxorubicin, have been associated with higher incidences of cardiotoxicity [13]. Additionally, gender and age have also been identified as potential factors influencing the risk. Furthermore, cumulative dose, as well as electrolyte imbalances, such as low calcium or magnesium levels, have been implicated as potential contributing factors [14], warranting further investigation and control of such cases to establish correlations. Moreover, the type of malignancy appears to have an impact on the incidence of cardiotoxicity. In our study, breast and gastrointestinal malignancies exhibited the highest rates, both at 27.6%, which aligns with findings from prior studies [15,16].
Cancer and cardiovascular disease share common risk factors, including aging, physical inactivity, smoking, hypertension, diabetes mellitus, and inflammation, all of which contribute significantly to the progression and development of both entities [2,6,17]. Additionally, the presence of pre-existing cardiovascular conditions renders patients more susceptible to cardiotoxicity and other cardiac events, potentially leading to treatment modifications, dose adjustments, or even premature discontinuation of therapy [15,16,18]. In our study, a history of heart disease, impaired baseline ejection fraction, and dyslipidemia were associated with cardiac toxicity. However, no significant associations were found with age, smoking, hypertension, chronic renal failure, or diabetes. Consistent with our findings, previous studies have also reported associations between cardiac toxicity and a history of heart disease, dyslipidemia, and impaired baseline ejection fraction [16,19]. Another study reported a higher prevalence of cardiovascular events among individuals with a history of hypertension, dyslipidemia, and smoking [20]. Although our analysis did not find a significant association between smoking and cardiotoxicity, it is worth noting that smoking has been linked to increased chemotherapy toxicity and poorer overall outcomes [21]. The limited sample size of our study patients and the unknown patterns within smaller smoking groups should not be interpreted as a lack of potential association.
Similarly, our analysis did not find significant associations between age, hypertension, chronic renal failure, and diabetes with cardiotoxicity. It is important to note that various studies have reported different findings regarding age as a risk factor for cardiotoxicity, with some suggesting an increased risk in both younger and older patients, particularly in the context of anthracycline-based chemotherapy [22,23]. Furthermore, hypertension and diabetes are well-established risk factors for cardiovascular disease and have been observed to be associated with a higher incidence of cardiotoxicity among breast cancer patients receiving trastuzumab [24]. Although our study did not find a statistically significant association, it is important to consider that our sample size was relatively small, and we had a predominantly younger population, with the majority of patients being under 60 years of age.
The advancement of more potent anticancer therapy drugs has undoubtedly improved patient outcomes in cancer treatment. However, it is important to acknowledge that these drugs can also come with substantial short-term and long-term toxicities [25]. Therefore, patients who have been exposed to chemotherapeutic agents known to increase the risk of heart failure, such as anthracyclines, trastuzumab, sunitinib, and sorafenib, should undergo screening to assess the stage of their heart failure. This screening should be based on the guidelines set forth by the American College of Cardiology/American Heart Association [26,27]. In our study, we observed a higher likelihood of cardiac toxicity among individuals who received specific chemotherapy subtypes, including monoclonal anticancer agents, alkylating agents, anthracyclines, hormonal agents, or taxanes. Additionally, those who received multiple anticancer therapy subtypes also showed an increased risk, although these findings did not reach statistical significance (p=0.274 and 0.653). It is worth noting that these agents have been associated with different clinical manifestations of cardiotoxicity [28].
Ongoing research is exploring the potential benefits of administering beta-blockers, ACE inhibitors, or angiotensin receptor blockers (ARBs), as preventive measures to avoid cardiotoxicity in patients undergoing cancer treatment [16,29]. In our study, approximately 21.1% of patients received cardiac protective agents, with ACE inhibitors and statins being the most commonly prescribed. Additionally, statin and antiplatelet were protective agents against cardiac toxicity and were statistically significant. Our goal is to transition from a reactive approach to a more proactive model for preventing cardiovascular toxicities associated with cancer therapies. In line with risk mitigation strategies employed in the general population, the field of cardio-oncology can also adopt preventive measures. The concept of cardio-oncology rehabilitation represents a paradigm shift in initiating proactive efforts, particularly for cancer patients at high risk of developing cardiac dysfunction [16,26].
Study limitations
This retrospective study was conducted at a single center, which limits the generalizability of the findings to other settings. Additionally, the sample size was relatively small. Therefore, the study's results represent a subset of cancer survivors and their cardiovascular studies. Additionally, it is important to acknowledge that the criteria for defining cardiotoxicity may vary across different healthcare facilities, highlighting the lack of a universally standardized assessment. This variation makes it challenging to compare and interpret results across studies accurately. Furthermore, the study did not adjust or classify patients based on additional factors such as total cumulative dose, infusion rate, speed, or the control of cardiovascular risk factors. These factors can potentially influence the development of cardiotoxicity and should be considered in future research. To advance knowledge in this area, future large-scale studies are required to address more specific questions and establish best practices for screening cancer survivors. By considering a broader range of factors and conducting comprehensive investigations, we can enhance our understanding and improve the management of cardiovascular health in this particular patient population.
Conclusions
Cardiotoxicity associated with anti-cancer therapy is a well-recognized phenomenon, underscoring the imperative for meticulous adherence to monitoring guidelines. Within the scope of this study, several factors have been identified as significant contributors to cardiotoxicity, including a history of prior heart disease, dyslipidemia, a low baseline ejection fraction, and the administration of multiple anticancer therapy treatments. These findings highlight the importance of proactive management strategies aimed at mitigating the potential cardiotoxic effects of anti-cancer therapies.
The authors have declared that no competing interests exist.
Human Ethics
Consent was obtained or waived by all participants in this study. Research Committees of King Khalid Hospital issued approval 2022-32E
Animal Ethics
Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.
References
- 1.Adriamycin (doxorubicin) cardiotoxicity: a review. Chlebowski RT. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1271861/ West J Med. 1979;131:364–368. [PMC free article] [PubMed] [Google Scholar]
- 2.Cardiotoxicity and cardiac monitoring among anthracycline-treated cancer patients: a retrospective cohort study. Alkofide H, Alnaim L, Alorf N, Alessa W, Bawazeer G. Cancer Manag Res. 2021;13:5149–5159. doi: 10.2147/CMAR.S313874. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Anticancer drug-induced cardiotoxicity: insights and pharmacogenetics. Adhikari A, Asdaq SM, Al Hawaj MA, et al. Pharmaceuticals (Basel) 2021;14:970. doi: 10.3390/ph14100970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Cancer therapy-related cardiac dysfunction: an overview for the clinician. Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Clin Med Insights Cardiol. 2019;13:1179546819866445. doi: 10.1177/1179546819866445. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Cardiotoxicity of anticancer therapeutics. Dong J, Chen H. Front Cardiovasc Med. 2018;5:9. doi: 10.3389/fcvm.2018.00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients. Johnson CB, Davis MK, Law A, Sulpher J. Can J Cardiol. 2016;32:900–907. doi: 10.1016/j.cjca.2016.04.008. [DOI] [PubMed] [Google Scholar]
- 7.Cardiovascular disease and cancer: is there increasing overlap? Vincent L, Leedy D, Masri SC, Cheng RK. Curr Oncol Rep. 2019;21:47. doi: 10.1007/s11912-019-0796-0. [DOI] [PubMed] [Google Scholar]
- 8.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. Eur Heart J. 2016;37:2768–2801. doi: 10.1093/eurheartj/ehw211. [DOI] [PubMed] [Google Scholar]
- 9.Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies: position paper of the Heart Failure Working Group of the Austrian Society of Cardiology. Bergler-Klein J, Rainer PP, Wallner M, et al. Wien Klin Wochenschr. 2022;134:654–674. doi: 10.1007/s00508-022-02031-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. Guglin M, Hartlage G, Reynolds C, Chen R, Patel V. J Card Fail. 2009;15:651–657. doi: 10.1016/j.cardfail.2009.04.011. [DOI] [PubMed] [Google Scholar]
- 11.Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM. CA Cancer J Clin. 2016;66:309–325. doi: 10.3322/caac.21341. [DOI] [PubMed] [Google Scholar]
- 12.Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, et al. Eur Heart J. 2020;41:1720–1729. doi: 10.1093/eurheartj/ehaa006. [DOI] [PubMed] [Google Scholar]
- 13.Mechanisms of cardiotoxicity of cancer chemotherapeutic agents: cardiomyopathy and beyond. Moudgil R, Yeh ET. Can J Cardiol. 2016;32:863–870. doi: 10.1016/j.cjca.2016.01.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Updated cardiovascular prevention guideline of the Brazilian Society of Cardiology - 2019. Précoma DB, Oliveira GM, Simão AF, et al. Arq Bras Cardiol. 2019;113:787–891. doi: 10.5935/abc.20190204. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology. Al-Kindi SG, Oliveira GH. Mayo Clin Proc. 2016;91:81–83. doi: 10.1016/j.mayocp.2015.09.009. [DOI] [PubMed] [Google Scholar]
- 16.Clinical experience of a cardio-oncology consultation at a tertiary university hospital in Portugal: an observational study. Fiuza M, Magalhães A, Nobre Menezes M, et al. Rev Port Cardiol. 2022;41:979–984. doi: 10.1016/j.repc.2021.07.014. [DOI] [PubMed] [Google Scholar]
- 17.Hypertension in long-term survivors of childhood cancer: a nested case-control study. Cardous-Ubbink MC, Geenen MM, Schade KJ, Heinen RC, Caron HN, Kremer LC, Van Leeuwen FE. Eur J Cancer. 2010;46:782–790. doi: 10.1016/j.ejca.2010.01.002. [DOI] [PubMed] [Google Scholar]
- 18.Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Bansal N, Adams MJ, Ganatra S, et al. Cardiooncology. 2019;5:18. doi: 10.1186/s40959-019-0054-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Trastuzumab-related cardiotoxicity among older patients with breast cancer. Chavez-MacGregor M, Zhang N, Buchholz TA, et al. J Clin Oncol. 2013;31:4222–4228. doi: 10.1200/JCO.2013.48.7884. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Brazilian cardio-oncology: the 10-year experience of the Instituto do Cancer do Estado de Sao Paulo. Costa IB, Bittar CS, Fonseca SM, et al. BMC Cardiovasc Disord. 2020;20:206. doi: 10.1186/s12872-020-01471-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Tobacco smoking after diagnosis of cancer: clinical aspects. Jassem J. Transl Lung Cancer Res. 2019;8:0–8. doi: 10.21037/tlcr.2019.04.01. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. J Clin Oncol. 1997;15:1544–1552. doi: 10.1200/JCO.1997.15.4.1544. [DOI] [PubMed] [Google Scholar]
- 23.Risk factors for doxorubicin-induced congestive heart failure. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM. Ann Intern Med. 1979;91:710–717. doi: 10.7326/0003-4819-91-5-710. [DOI] [PubMed] [Google Scholar]
- 24.Risk factors of trastuzumab-induced cardiotoxicity in breast cancer. A meta-analysis. Jawa Z, Perez RM, Garlie L, et al. Medicine (Baltimore) 2016;95:0. doi: 10.1097/MD.0000000000005195. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Cardiotoxicity of chemotherapy and targeted agents. Mudd TW Jr, Khalid M, Guddati AK. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085845/ Am J Cancer Res. 2021;11:1132–1147. [PMC free article] [PubMed] [Google Scholar]
- 26.Oncology and cardiac rehabilitation: an underrated relationship. Venturini E, Iannuzzo G, D'Andrea A, et al. J Clin Med. 2020;9 doi: 10.3390/jcm9061810. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Chemotherapy-related cardiomyopathy. Piper SE, McDonagh TA. Eur Cardiol. 2015;10:19–24. doi: 10.15420/ecr.2015.10.01.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Update on cardiotoxicity of anti-cancer treatments. Rosa GM, Gigli L, Tagliasacchi MI, et al. Eur J Clin Invest. 2016;46:264–284. doi: 10.1111/eci.12589. [DOI] [PubMed] [Google Scholar]
- 29.Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Kalam K, Marwick TH. Eur J Cancer. 2013;49:2900–2909. doi: 10.1016/j.ejca.2013.04.030. [DOI] [PubMed] [Google Scholar]